射频消融术和<sup>131</sup>I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

张金山; 邓咏梅

doi:10.3760/cma.j.issn.1673-4114.2009.03.008

射频消融术和¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

张金山^,,
邓咏梅

广州医学院第三附属医院核医学科, 广州 510150

通讯作者: 张金山, zhangjsgd137@163.com ;

基金项目:
广州市医药卫生科技一般引导项目(2007-YB-238)

Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

ZHA NG din-shan^,,
DENG Yong-mei

Department of Nuclear Medicine, the Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, China, 510150

Corresponding author: ZHA NG din-shan, zhangjsgd137@163.com ;

摘要: 射频消融(RFA)被认为是一种新型的肺癌病灶局部控制的微创治疗方法,具有方法操作简便、安全可靠、无全身不良反应、对肺癌有较高局部控制率等优点,但对于瘤体负荷较大的肿瘤病灶(如肿瘤直径3cm以上)治疗风险大、疗效欠佳。以变性和(或)坏死的肿瘤细胞核抗原作为结合靶点的新型放射免疫治疗即¹³¹I标记的基因重组肿瘤细胞核单抗的肿瘤坏死治疗法为肿瘤的治疗提供了新途径,然而¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗肺癌的完全缓解率低。RFA扩大了肿瘤坏死区而有效增加了¹³¹I-肿瘤细胞核人鼠嵌合单抗结合的靶点,故RFA联合¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗呵望明显提高对肺癌的治疗效果。
- 肺肿瘤 /
- 碘放射性同位素 /
- 肿瘤细胞核人鼠嵌合单抗 /
- 射频消融
Abstract: Radiofrequency ablation (RFA)is an advanced, minimally invasive technique in the treatment of patients with lung cancer and has been found to be both safe and technically feasible with a high local efficacy, but for he size of the lesion is over 3.0 cm diameter there is less effective. Iodine-131-labeled nuclei of tumor cells chimeric monoclonal antibody, a novel radioimmunotherapy provided a new therapeutic approaches for lung cancer, but the complete response is low. For RFA can induce a mass complete tumor necrosis which greatly increase the targeting area for radioimmunotherapy, thus RFA followed by ¹³¹I-nuclei of tumor cells chimeric monoclonal antibody adjuvant treatment may apparently improve the therapeutic efficacy of lung cancer, especially for tumors larger than 3.0 cm diameter.
- Lung neoplasms /
- Iodine radioisotopes /
- Tumor cells chimeric monoclonal antibody /
- Radiofrequency ablation
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	邹小农.中国肺癌流行病学.中华肿瘤防治杂志,2007,14(12):881-883.
[2]	白春学,张新.肺癌的治疗现状.中华结核和呼吸杂志,2006,29(3):146-148.
[3]	Matsunka T, Okuma T. CT-guided radioffequency ablation for tung cancer. Int J Clin Oncol, 2007, 12(2):71-78.
[4]	Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. Am J Roentgenol, 2000, 174(1):57-59.
[5]	殷伟强,何建行,徐鑫,等.CT定位下经皮穿刺射频消融治疗肺肿瘤疗效分析.中国实用外科杂志,2006,26(3):219-221.
[6]	肖越勇,李家开,田锦林,等.CT导向下周围型肺癌射频消融治疗的临床分析.中华放射学杂志,2006,40(12):1317-1319.
[7]	Gadaleta C, Mattiuli V, Colueei G, et al. Radiofrequency ablation of 40 lung neoplasms:preliminary results. Am J Roentgenol, 2004, 183(2):361-368.
[8]	Laganà D, Carrafiello G, Mangini M, et al. Radiofrequency ablation of primary and metastatic lung tumors:preliminary experience with a single center device. Surg Endosc, 2006, 20(8):1262-1267.
[9]	Akeboshi M, Yainakado K, Nakatsuka A, et al. Percutaneous radinfrequency ablation of lung neoplasms:initial therapeutic response. J Vase lnterv Radiol, 2004, 15(5):463-470.
[10]	Yamakado K, Hase S, Matsuoka T, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with eolorectal cancer:a multieenter study in Japan. J Vase lnterv Radiol, 2007, 18(3):393-398.
[11]	Ambrogi MC, Lucchi M, Dini P, et al. Percutaneous radiofrequency ablation of lung tumours:results in the mid-term. Eur J Cardiothorac Surg, 2006, 30(1):177-183.
[12]	Pennathur A, Luketich JD, Abbas G, et al. Radioffequeney ahlation for the treatment of stage I ram-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg, 2007, 134(4):857-864.
[13]	Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation tollowed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest, 2006, 129(3):738-745.
[14]	de Babère T, Palussière J, Aupérin A, et al. Midterm local efficacy and survival after radiofrequeney ablation of lung tumors with minimum follow-up of 1 year:prospective evaluation. Radiology, 2006, 240(2):587-596.
[15]	Hiraki T, Tajiri N, Mimura H, et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequeney ablation of lung tumors:incidence and risk factors. Radiology, 2006, 241(1):275-283.
[16]	Nomura M, Yamakado K, Nomoto Y, et al. Complications after lung radiofrequency ablation:risk factors tor lung inflammation. Br J Radiol, 2008, 81(963):244-249.
[17]	Hataji O, Yamakado K, Nakatsuka A, et al. Radiological and pathological correlation of lung malignant tumors treated with percutaneous radiofrequency ablation. Intern Med, 2005, 44(8):865-869.
[18]	Steinke K, Haghighi KS, Wulf S, et al. Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo:preliminary results. J Surg Res, 2005, 124(1):85-91.
[19]	Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med, 2004, 34(1 suppl 1):4-9.
[20]	Dillman, RO. Radiolabeled anti-CD20 monolonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol, 2002, 20(16):3545-3557.
[21]	Kennel SJ, Davis IA, Branning J, et al. High resolution computed tomography and MR1 for monitoring lung tumor growth in mice undergoing radioimmunotherapy:correlation with histology. Med Phys, 2000, 27(5):1101-1107.
[22]	Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med, 2002, 43(5):693-713.
[23]	Goldenberg DM. Advaneing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother, 2003, 52(5):281-296.
[24]	von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Ann Rev Med, 2003, 54:343-369.
[25]	Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res, 1988, 48(20):5842-5848.
[26]	Khawli LA, Alauddin MM, Hu P, et al. Tumor targeting properties of indium-Ill labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm, 2003, 18(6):931-940.
[27]	傅相平,李安民,张志文,等.¹³¹I-肿瘤细胞核人鼠嵌合单抗脑胶质瘤瘤内放免治疗研究.中华实验外科杂志,2005,22(1):102-103.
[28]	于力克,徐兆强,陈文萍,等.¹³¹I-chTNT导向治疗晚期肺癌的临床研究.中国肺癌杂志,2002,5(6):931-940.
[29]	Yu L, Ju DW, Chen W, et al. ¹³¹I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm, 2006, 21(1):5-14.
[30]	Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol, 2005, 23(7):1538-1547.

[1]	姚红霞 , 张金山 . 微波消融和¹³¹I-肿瘤细胞核人鼠嵌合单克隆抗体联合治疗肺癌. 国际放射医学核医学杂志, 2012, 36(5): 264-268, 306. doi: 10.3760/cma.j.issn.1673-4114.2012.05.002
[2]	李亚军 , 白人驹 , 高硕 , 李彦生 , 刘磊 , 贾薇 , 蔡莉 , 邢喜玲 . 兔VX2肺肿瘤PET-CT与血管生成的相关性研究. 国际放射医学核医学杂志, 2010, 34(3): 139-142. doi: 10.3760/cma.j.issn.1673-4114.2010.03.003
[3]	夏伟 , 吕中伟 , 王国玉 , 侯仁花 , 蔡海东 , 袁雪宇 . ⁹⁹Tc^m标记depreotide及与肺腺癌A549细胞亲和性研究. 国际放射医学核医学杂志, 2010, 34(4): 193-197. doi: 10.3760/cma.j.issn.1673-4114.2010.04.001
[4]	邓智勇 , 杨丽春 . 肺肿瘤核素显像的临床应用进展. 国际放射医学核医学杂志, 2008, 32(5): 295-299.
[5]	高玉杰 , 周妮娜 , 李雨奇 , 张伟 , 张鹏博 , 罗晓燕 . ¹⁸F-FDG PET/CT纹理分析在肺癌与肺结核的高代谢孤立性肺结节鉴别诊断中的增益价值. 国际放射医学核医学杂志, 2022, 46(2): 73-79. doi: 10.3760/cma.j.cn121381-202011001-00126
[6]	朱晓珉 , 方文岩 , 陈军 , 赵成 , 陈鹏 . CT导向下¹²⁵I粒子植入治疗难治性肺癌的疗效观察. 国际放射医学核医学杂志, 2011, 35(2): 114-117. doi: 10.3760/cma.j.issn.1673-4114.2011.02.012
[7]	田亚东 , 袁卫红 . 影像学及肿瘤相关抗原在诊断肺癌中的应用. 国际放射医学核医学杂志, 2011, 35(5): 295-299. doi: 10.3760/cma.j.issn.1673-4114.2011.05.011
[8]	张高潮 , 马丽 , 寇莹 , 陈正福 , 宋晏 , 徐金亮 . ⁹⁹Tc^m-tetrofosmin SPECT诊断肺部肿瘤的临床价值. 国际放射医学核医学杂志, 2015, 39(4): 303-307. doi: 10.3760/cma.j.issn.1673-4114.2015.04.007
[9]	郭睿 , 李彪 . 钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2010, 34(3): 147-151. doi: 10.3760/cma.j.issn.1673-4114.2010.03.005
[10]	谭兴普 , 黄艳 . ⁹⁹Tc^m-MIBI亲肿瘤延迟断层显像对肺占位病灶的诊断价值. 国际放射医学核医学杂志, 2010, 34(5): 297-299. doi: 10.3760/cma.j.issn.1673-4114.2010.05.012

点击查看大图

计量

文章访问数: 1837
HTML全文浏览量: 325
PDF下载量: 2

射频消融术和¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

通讯作者: 张金山, zhangjsgd137@163.com ;

Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

Corresponding author: ZHA NG din-shan, zhangjsgd137@163.com ;

计量

射频消融术和¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

通讯作者: 张金山, zhangjsgd137@163.com;

English Abstract

Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

Corresponding author: ZHA NG din-shan, zhangjsgd137@163.com

全文HTML

目录

射频消融术和131I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

通讯作者: 张金山, zhangjsgd137@163.com ;

Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

Corresponding author: ZHA NG din-shan, zhangjsgd137@163.com ;

计量

出版历程

射频消融术和131I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

通讯作者: 张金山, zhangjsgd137@163.com;

English Abstract

Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

Corresponding author: ZHA NG din-shan, zhangjsgd137@163.com

全文HTML

目录

射频消融术和¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

射频消融术和¹³¹I-肿瘤细胞核人鼠嵌合单抗治疗肺癌